The protein sequencing market is witnessing a rising demand driven by the growing importance of understanding the structure and function of proteins in various biological processes. Protein sequencing plays a pivotal role in proteomics, drug discovery, and biopharmaceutical development.
Continuous improvements in the next-generation sequencing technologies are playing a significant role on how market trends develop. NGS technology platforms have begun to be increasingly used for high-throughput protein sequencing, allowing researchers to obtain more rapid and precise methods of determining complex proteins.
The growing interest in personalized medicine is generating the demand for protein sequencing. Knowledge of the diversity in protein sequences is essential for developing precision therapies based on patient profiles and, consequently, drives sequencing technologies into medical practice.
Protein sequencing is much more important in drug development. The pharmaceutical industry focuses on biologics and precision medicine, thus the requirements of more detailed protein structures contribute to increased use of sequencing techniques in drug discovery.
The use of third-generation sequencing technologies widens the potentials of protein sequencing. Advances in single molecule sequencing technologies, including PacBio and Nanopore Sequencing give longer reads that allow more accurate identification of protein consequences as well as post-translational modifications.
Protein sequencing is the core of biomarker discovery for a number of diseases. It is possible to determine specific protein signatures for diseases, which in turn leads to the emergence of diagnostic tools and targeted therapies that predetermine market conditions.
Proteomic research is one of the key components for protein sequencing market growth. Schols in academia and industry are using protein sequencing to solve problems with how cellular processes work, understand proteins that interact among themselves as well as develop biomarkers for prognosis of diseases.
While technology is improving, issues remain in de novo sequencing for proteins that are largely complicated. Another focus area of improving the accuracy and speed in terms of de novo sequencing methods has been step towards making protein sequence identification more reliable.
One of the most significant trends is to combine artificial intelligence (AI) with protein sequence analysis. The interpretation of complex sequencing data is currently carried out using AI algorithms, which increase the accuracy and speed of protein sequence identification as well as posttranslational modification identification.
Cost reduction and scalability of protein sequencing technologies are increasingly being stressed. Companies are actively working towards the identification of cost-effective and scalable sequencing implementations to bring these technologies into broader research and clinical applications.
The Proteomics market is growing due to the international spread of this kind of research. Collaborations between research institutions and biotechnology companies are enabling the transfer of skills and resources to improve protein sequencing technologies.
Public and private initiatives focused on advancing proteomics and protein sequencing technologies are influencing market trends. Funding and support from government bodies, research organizations, and industry consortia are driving innovation and accelerating the development of novel sequencing techniques.
Protein Sequencing Market Size was valued at USD 0.8 Billion in 2023. The Global Protein Sequencing industry is projected to grow from USD 0.85 Billion in 2024 to USD 1.34 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.89% during the forecast period (2024 - 2032).
Protein sequencing technologies are used to determine and analyze the amino acid sequences of proteins or peptides. Increased focus on target-based medication development by biotechnology and pharmaceutical companies, as well as increased financial support for proteome research from the public and commercial sectors.
Advancements in clinical mass spectrometry and analytical techniques are some of the factors that are expected to drive market growth during the forecast period. The National Cancer Institute Office of Cancer Clinical Proteomics Research, for example, offers funding options for proteomics research. However, the high cost of infrastructure and equipment may limit the expansion of the protein sequencing market over the assessment period.
Thermo Fisher Scientific, the largest life sciences company worldwide, and Olink Holding, a leading provider of next-generation proteomic solutions, announced on October 17th, 2023, that their respective boards have approved the proposal of Thermo Fisher to acquire Olink at a price of US$26.00 per common share in cash or US$26.00 per American Depository Share (ADS) in cash.
American manufacturer of scientific instruments Bruker Corporation announced on June 5th, 2023, that it drastically increased the sensitivity of its timsTOF platform for 4D-Proteomics with the introduction of the new times of Ultra mass spectrometer including a novel Capillary Spray Ionization (CSI) ultra source with large capillary and optimized vortex gas flow as well as a newly designed fourth generation TIMS XR (trapped ion mobility separation) cell and 14bit digitizer.
In December 2022, Quantum-Si Incorporated declared launching Platinum; this is considered the world’s first-ever novel next-generation single-molecule protein sequencing platform.
In September 2022 NVIDIA Corporation promised to integrate NeMo LLM cloud services through BioNeMO so as to allow for biological and chemical pre-trained language models access by academics. The services facilitate research interaction while manipulating data plus proteins for various applications such as drug discovery.
Amphista Therapeutics, which seeks to develop small molecule protein degraders and Bristol Myers Squibb entered into partnership in May 2022. There is likely going to be an exclusive license for production and marketing, given that product.
For instance, researchers from the University of Texas in January 2022 revealed a practical way towards single-molecule protein sequencing. Thus, market growth will result due to technological advances in protein-sequencing techniques.
Collaboration between Amgen and Generate Biomedicines was given birth in January 2022 for the discovery and development of protein-based therapies across multiple areas. The deal is expected to cost around USD 1.9 billion.
The protein sequencing market has been segmented into products and services, technology, application, and end user.
By products and services, the market has been segmented into reagent and consumables, instruments, analysis products/software, and protein sequencing services. The instrument segment has been further segmented into mass spectrometry instruments and Edman degradation sequencers. The reagents and consumables segment accounted for the largest share of the protein sequencing products market in 2017. The factors such as ongoing advancements in protein sequencing technologies and the rising number of sequencing procedures are expected to boost the growth of the segment.
On the basis of technology, the market has been segmented into mass spectrometry and Edman degradation.
On the basis of application, the market has been segmented into biotherapeutics, genetic engineering, and others. The biotherapeutics segment is anticipated to be the fastest growing segment during the forecast period.
The market, by end user, has been segmented into pharmaceutical and biotechnology companies, academic institutes and research centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The protein sequencing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European protein sequencing market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The protein sequencing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The protein sequencing market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global protein sequencing market owing to the rising application of protein sequencing in proteomic research, the development of protein sequencing, and availability of research funding in the region. For instance, in September 2016, the National Institute of Health (NIH) announced to fund for research on Proteomics, Immunoassay for TB Activation in HIV Patients.
Europe is expected to hold the second largest position in the global protein sequencing market. The market growth in this region is attributed to the increasing proteomics research and the availability of funding and infrastructure for research. For instance, PRIME-XS is a consortium of 12 European research institutes. It is a pan-European infrastructure for proteomics research.
The protein sequencing market in the Asia-Pacific region consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the Rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the increase in government funding for healthcare, rising R&D expenditure, and a growing number of biopharmaceutical companies.
The Middle East and Africa has the lowest share of the global protein sequencing market. Majority of the market of the region is anticipated to be held by the Middle Eastern region owing to the growing government initiatives for the healthcare sector.
Global Protein Sequencing Market Share (%), by Region, 2022
Source: White Papers, Company Presentations, Annual Reports
BSI's objective is to make a positive influence in proteomic research, particularly by offering professionally supported software. Bioinformatics Solutions Inc. creates powerful algorithms based on cutting-edge research to solve basic bioinformatics difficulties. This small, agile team is dedicated to meeting the demands of pharmaceutical, biotechnological, and academic scientists, as well as advancing drug discovery research. The firm, started in 2000 in Waterloo, Canada, is comprised of a bright, award-winning, and clever crew of developers, scientists, and salespeople.
Charles River Laboratories International, Inc. offers drug discovery and development solutions such as research models and related services, as well as outsourced preclinical services. Segments the business is divided into two divisions: The firm produces and sells research models, mostly genetically and virally specified purpose-bred rats and mice, with roughly 150 distinct strains. It also offers a variety of complementary services to help clients support the usage of research models in medication development.
Intended Audience
Key players:
are some of the key players in the global protein sequencing market.
The report for Protein Sequencing Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)